- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07564739
Study of Tolerance to the Application of Cold Plasma in the Treatment of Chronic Wounds (PLASMA-SAFE)
Chronic wounds affect many patients, with no downward trend in recent decades. This is a significant economic and social issue, and this condition has an impact on functional disabilities and quality of life, especially among the elderly. Diagnosis is essentially clinical, and there are many causes, but 90% of leg ulcers, for example, are primarily vascular in origin. There are wounds of traumatic, post-operative, and vascular origin, as well as pressure sores. The main purpose of invasive tests is to objectively determine the cause (arterial damage) or to check for underlying osteitis. Chronic wounds are usually infected or colonized by bacteria from the skin and digestive flora. There is no indication for antibiotic therapy in the treatment of wounds. Nursing staff play an important role in therapeutic management, which must be carried out in harmony with other healthcare professionals, such as general practitioners and specialists. This management has two main goals: to accelerate the epidermalization of chronic wounds, or even their healing, and to limit local and general complications, the recurrence of which remains the most difficult to control. There are many types of healing dressings available, adapted to each type of ulceration: fibrinous, necrotic, superinfected, etc.
Nevertheless, innovative solutions can accelerate healing, thereby reducing hospital stays, disabilities associated with chronic wounds, and complications such as skin-related septicemia. Research efforts may focus on the use of growth factors, for example, for old or stubborn forms of the disease, despite proper medical treatment, or on any other innovative technique.
The properties of cold plasma appear to be suitable for the treatment of chronic wounds, as has been demonstrated in cell models, animal models, and with argon plasma in several countries around the world on an experimental basis in humans.
The GREMI in Orléans has acquired internationally recognized expertise in the technique of cold helium plasma. The combination of this applied research laboratory and the Infectious Diseases Department of the Orléans University Hospital has led to the development of relationships that have resulted in the proposal to conduct this study, based in its first phase on the evaluation of the medical device's tolerance.
Visão geral do estudo
Status
Condições
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Thierry PRAZUCK, PH
- Número de telefone: +332 38 51 43 61
- E-mail: thierry.prazuck@chu-orleans.fr
Locais de estudo
-
-
-
Orléans, França, 45000
- Recrutamento
- Centre Hospitalier Universitaire d'Orléans, France
-
Investigador principal:
- Thierry PRAZUCK, MD
-
Contato:
- Thierry PRAZUCK, MD
- E-mail: thierry.prazuck@chu-orleans.fr
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Men or women.
- Aged 18 years or older.
- Chronic wound or ulceration.
- Wound measuring 5 to 100 cm² of arterial or venous origin.
- Evolution > 4 weeks.
- With less than 30% necrosis.
- Able to give informed written consent.
- Blood pregnancy test for women of childbearing age.
Exclusion Criteria:
- Tumor wounds
- Dialysis
- Patients requiring surgical revascularization
- Severe heart failure (NYHA III-IV) or acute myocardial infarction.
- Wounds or ulcers located less than 10 cm from the patient's airways and respiratory tract
- Severe renal failure defined as creatinine clearance <20 mL/min calculated according to the MDRD
- Patients with severe hepatic impairment (class C) according to the Child Pugh score
- Unstable liver disease (defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice), cirrhosis, known biliary abnormality.
- Active malignant tumor
- Patients who, in the investigator's opinion, are at significant risk of suicide
- Any pre-existing physical or mental condition that may interfere with the patient's ability to comply with the administration schedule and/or protocol assessments, or that may compromise the patient's safety.
- Persons covered by Articles L.1121-5 to L.1121-8 and L.1122-1-2 of the Public Health Code (including minors and protected adults)
- Protected person (under guardianship or curatorship)
- Person under judicial protection
- Persons deprived of their liberty
- Persons not affiliated with a social security system
- Women who are pregnant or breastfeeding, or who plan to become pregnant or breastfeed during the study.
- Patients participating in another clinical trial evaluating a treatment
- Allergy to the dressings used in the trial
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Plasma treatment with exposure 1 min/10 cm² + conventional treatment
|
The plasma will be applied using the multi-jet probe by an investigating physician over the entire surface of the ulceration during the defined exposure times (1min/10 cm2), after which the nurse will apply the standard dressing appropriate for the characteristics of the ulceration. The sessions will be repeated daily for 8 days. |
|
Experimental: Plasma treatment with exposure 3 min/10 cm² + conventional treatment
|
The plasma will be applied using the multi-jet probe by an investigating physician over the entire surface of the ulceration during the defined exposure times (3min/10 cm2), after which the nurse will apply the standard dressing appropriate for the characteristics of the ulceration.
|
|
Experimental: Treatment using dressings impregnated with ions induced by exposure to plasma
|
The plasma will be applied using the multi-jet probe by an investigating physician over the dressing, after which the nurse will apply the dressing on the ulceration.
|
|
Sem intervenção: Conventional treatment with hydrocolloid dressing or adapted dressing, local care
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
|---|---|
|
Level of local inflammation
Prazo: Everyday for 8 days
|
Everyday for 8 days
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in the size of the ulcer
Prazo: Day 0, Day 2, Day 4, Day 6 and Day 7
|
Measurement of the wound area using MolecuLight for daily photographies and computer analysis of the images
|
Day 0, Day 2, Day 4, Day 6 and Day 7
|
|
Change in the extent of tissue loss
Prazo: Day 0, Day 2, Day 4, Day 6 and Day 7
|
Measuring wound volume with the MolecuLight
|
Day 0, Day 2, Day 4, Day 6 and Day 7
|
|
semi-quantitative change in total bacterial load
Prazo: Day 0 and day 7
|
semi-quantitative change in total bacterial load between Day 0 and Day 7 on bacterial samples taken from the base of the ulcer
|
Day 0 and day 7
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- CHUO-2024-03
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .